•The tri-modalities of chemoradiotherapy (CRT) with IMRT and durvalumab were evaluated.•We have reported the efficacy and safety of tri-modalities through real-world data.•A better response to CRT and increasing radiation dose are related to long PFS.•Durvalumab therapy duration was linked to survival in patients.
